BAKX Therapeutics

Team
Science
Platform
Pipeline
Media & Publications
Careers

Nature Communications

March 7, 2022
Nature Communications

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
read more

We want to hear from you.

© 2022 BAKX Therapeutics. All rights reserved.

New York
Boston
Press

LinkedIn
Twitter